Last reviewed · How we verify
Esketamine at low dose
At a glance
| Generic name | Esketamine at low dose |
|---|---|
| Also known as | Esketamine Hydrochloride Injection |
| Sponsor | Tianjin Medical University General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study (NA)
- The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression (PHASE4)
- Efficacy of Esketamine for Patients With Irritable Bowel Syndrome (NA)
- The Effect of Esketamine Combined With Dexmedetomidine on Postoperative Recovery Quality in Patients Undergoing Thoracoscopic Surgery (NA)
- Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery (PHASE4)
- Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality (PHASE4)
- Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes (PHASE4)
- Analgesic Effects of Low-dose S-ketamine in Major Spine Fusion Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Esketamine at low dose CI brief — competitive landscape report
- Esketamine at low dose updates RSS · CI watch RSS
- Tianjin Medical University General Hospital portfolio CI